ScPharmaceuticals Sees Prelim. FY23 FUROSCIX Revenue $13.4M-$13.6M Vs $12.82M Est.
Portfolio Pulse from Benzinga Newsdesk
ScPharmaceuticals projects preliminary FY23 FUROSCIX revenue to be between $13.4M and $13.6M, surpassing the estimated $12.82M.
January 04, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ScPharmaceuticals anticipates higher-than-expected FY23 revenue for FUROSCIX, estimating a range of $13.4M to $13.6M versus the $12.82M analysts predicted.
The positive revenue forecast for ScPharmaceuticals' FUROSCIX is likely to be viewed favorably by investors, as it exceeds analyst expectations. This could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100